OUR SCIENCE

We have been early innovators in the field of immuno-oncology. Now, we are building on that expertise to develop current and next-generation immuno-oncology medicines that harness the patient’s immune system to fight cancer. Our active areas of research include:

• Stimulating and reprogramming tumor specific T cell response, novel therapeutics that leverage natural killer (NK) cell function, and new concepts to address resistance to checkpoint inhibition
• Leveraging myeloid cell function to either directly attack the tumor or to stimulate tumor specific T cell responses through myeloid cell biology